1. Scrip
  2. >>Business

Keeping An Eye On Regeneron: What's Next To Drive Growth

 
• By Jessica Merrill

Regeneron is looking to expansion of Eylea to diabetic retinopathy and Dupixent to asthma and other indications to drive mid-term growth. The firm is poised to file a PD-1 inhibitor with FDA in Q1.

Man with report

With two new drug launches under its belt in 2017 – Dupixent (dupilumab) for atopic dermatitis and Kevzara (sarilumab) for rheumatoid arthritis – investors want to know what is next on the horizon to drive growth at Regeneron Pharmaceuticals Inc. Most of the biotech's near-term growth prospects hinge on the continued strength of its workhorse Eylea (aflibercept), the success of the new launches and the expansion of existing drugs into new indications.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Earnings

More from Business

Transient FY26 For Syngene But Momentum In China +1 Projects

 
• By Anju Ghangurde

As biopharma derisks its business with China ‘rebalancing’ strategies, Syngene could convert majority of such pilots into full program contracts amid a challenging FY2025. The CRDMO also expects business discussions pertaining to a newly acquired US biologics site to mature into commercial opportunities.

Biogen’s Manufacturing Sites, Revenue Sources Protect It From Big Tariff Impact

 
• By Mandy Jackson

Biogen expects little impact from existing tariffs and any that may apply if the US exemption of pharma products is lifted, since 75% of its manufacturing is in the US and 55% of sales are ex-US.

Amgen Under Pressure, But Seeing Gains Ahead Of Obesity Readouts

 
• By Mandy Jackson

MariTide could give Amgen a big boost if successful in obesity, but the drug just entered Phase III. Even so, Q1 revenue rose 9% to $8.15bn and more growth is expected in 2025.